Renoprotective effects of blockade of angiotensin II AT1 receptors in an animal model of type 2 diabetes

Hypertension Research

Volumn 25, Issue 2, 2002, Pages 271-278

  Mizuno, Makoto ^a   Sada, Toshio ^a   Kato, Mikio ^a   Koike, Hiroyuki ^a  

^a DAIICHI SANKYO CO   (Japan)

Author keywords

Angiotensin receptor blocker; Nephropathy; Type 2 diabetes; Zucker diabetic fatty rat

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; GLUCOSE; INSULIN; OLMESARTAN; PENTOBARBITAL; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DIET; DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; GLOMERULOPATHY; GLUCOSE BLOOD LEVEL; HISTOLOGY; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTENSION; INSULIN BLOOD LEVEL; KIDNEY TUBULE DISORDER; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEINURIA; RAT;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CYTOPROTECTION; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; IMIDAZOLES; INSULIN; KIDNEY; LIPIDS; MALE; PROTEINURIA; RATS; RATS, INBRED STRAINS; RATS, ZUCKER; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, ANGIOTENSIN; SERUM ALBUMIN; TETRAZOLES;

EID: 0036236554     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.25.271     Document Type: Article

References (34)

1. Need for an incentive-based reimbursement policy toward quality care for dialysis patient management
2. End-stage renal failure in type 2 diabetes: A medical catastrophe of world-wide dimensions
3. Renoprotection and renin-angiotensin system blockade in diabetes mellitus
4. Screening and management of microalbuminuria in patients with diabetes mellitus: Recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc committee of the Council on National Kidney Foundation
5. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
6. Comparison of enalapril and nifedipine in treating non-insulin dependent diabetes associated with hypertension: One year analysis
7. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
8. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
9. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
10. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats
11. Angiotensin II subtype-1 receptor antagonists improve hemodynamic and renal changes without affecting glucose metabolisms in genetic rat model of non-insulin-dependent diabetes mellitus
12. Role for angiotensin II in an overt functional proteinuria
13. Long-term infusion of kallikrein attenuates renal injury in Dahl salt-sensitive rats
14. Evolution of metabolic and renal changes in the ZDF/Drt-fa rat model of type II diabetes
15. Profiling of Zucker diabetic fatty rats in their progression to the overt diabetic state
16. Fasting hyper-glycemia in non-insulin-dependent diabetes mellitus: Contributions of excessive hepatic glucose production and impaired tissue glucose uptake
17. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy
18. KRH-594, a new angiotensin AT1 receptor antagonist, ameliorates nephropathy and hyperlipidaemia in diabetic spontaneously hypertensive rats
19. Lipid abnormalities in renal disease (clinical conference)
20. Lipid abnormalities in the nephrotic syndrome: Causes, consequences, and treatment
21. Angiotensin II receptor antagonist treatment lowers plasma total cholesterol and very low + low density lipoprotein cholesterol in type 1 diabetic patients with albuminuria without affecting plasma cholesterol cholesteryl ester transfer
22. Pharmacology of CS-866, a novel nonpeptide angiotensin II receptor antagonist
23. Long-term effects of olmesartan, an Ang II receptor antagonist, on blood pressure and the renin-angiotensin-aldosterone system in hypertensive patients
24. Renal protective effects of blocking the intrarenal renin-angiotensin system: Angiotensin II type I receptor antagonist compared with angiotensin converting enzyme inhibitor
25. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes
26. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy
27. Differential effects of angiotensin II and transforming growth factor beta on the production of heparan sulfate proteoglycan by mesangial cells in vitro
28. Angiotensin actions in the kidney: Renewed insight into the old hormone
29. Angiotensin II causes mesangial cell hypertrophy
30. Angiotensin II induces superoxide anion production by mesangial cells
31. Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation
32. Role of oxidative stress in development of complications in diabetes
33. Effect of angiotensin convertase inhibitors and AT1 angiotensin receptor antagonists on the development of oxidative stress in the kidney of diabetic rats
34. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38